インヒビターの有無にかかわらず、血友病AまたはBの患者におけるコンシズマブの効果に関する研究

基本情報

NCT ID

NCT05135559

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

153

治験依頼者名

Novo Nordisk A/S

概要

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)